Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease
- PMID: 19124761
- PMCID: PMC2646375
- DOI: 10.4049/jimmunol.182.2.1174
Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease
Abstract
Host defenses, while effecting viral clearance, contribute substantially to inflammation and disease. This double action is a substantial obstacle to the development of safe and effective vaccines against many agents, particularly respiratory syncytial virus (RSV). RSV is a common cold virus and the major cause of infantile bronchiolitis worldwide. The role of alphabeta T cells in RSV-driven immunopathology is well studied, but little is known about the role of "unconventional" T cells. During primary RSV challenge of BALB/c mice, some Vgamma7+ gammadelta T cells were present; however, immunization with a live vaccinia vector expressing RSV F protein substantially enhanced Vgamma4+ gammadelta T cell influx after RSV infection. Harvested early, these cells produced IFN-gamma, TNF, and RANTES after ex vivo stimulation. By contrast, those recruited 5 days after challenge made IL-4, IL-5, and IL-10. Depletion of gammadelta T cells in vivo reduced lung inflammation and disease severity and slightly increased peak viral replication but did not prevent viral clearance. These studies demonstrate a novel role for gammadelta T cells in the development of immunopathology and cellular influx into the lungs after immunization and RSV challenge. Though a minor population, gammadelta T cells have a critical influence on disease and are an attractive interventional target in the alleviation of viral lung disease.
Figures
![FIGURE 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646375/bin/ukmss-3904-f0001.gif)
![formula image](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646375/bin/ukmss-3904-ig0008.jpg)
![FIGURE 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646375/bin/ukmss-3904-f0002.gif)
![FIGURE 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646375/bin/ukmss-3904-f0003.gif)
![FIGURE 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646375/bin/ukmss-3904-f0004.gif)
![FIGURE 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646375/bin/ukmss-3904-f0005.gif)
![FIGURE 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646375/bin/ukmss-3904-f0006.gif)
![FIGURE 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646375/bin/ukmss-3904-f0007.gif)
References
-
- Hall CB. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 2001;344:1917–1928. - PubMed
-
- Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am. J. Respir. Crit. Care Med. 2001;163:S2–S6. - PubMed
-
- Crowe JE. Respiratory syncytial virus vaccine development. Vaccine. 2001;20(Suppl. 1):S32–S37. - PubMed